HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ASG-5ME

consists of an IgG2kappa monoclonal antibody conjugated to monomethyl auristatin E

Networked: 4 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Anand, Banmeet: 1 article (10/2019)
2.	Antonarakis, Emmanuel S: 1 article (10/2019)
3.	Bruce, Justine: 1 article (10/2019)
4.	Chu, Rong: 1 article (10/2019)
5.	Danila, Daniel C: 1 article (10/2019)
6.	Eisenberger, Mario: 1 article (10/2019)
7.	Feldman, Jarett: 1 article (10/2019)
8.	Heath, Elisabeth I: 1 article (10/2019)
9.	Lackey, Jacqueline: 1 article (10/2019)
10.	McHugh, Deaglan: 1 article (10/2019)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 11/01/2016 - "Altogether, the data presented here suggest that ASG-5ME may have the potential to offer a new therapeutic option for the treatment of pancreatic and prostate cancers. " 10/01/2019 - "ASG-5ME, an SLC44A4-targeting antibody carrying monomethyl auristatin E (MMAE), a microtubule-disrupting agent, was investigated in men with metastatic castration resistant prostate cancer. " 11/01/2016 - "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer." 10/01/2019 - "A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer."
2.	Stomach Neoplasms (Stomach Cancer) 01/01/2016 - "This first-in-human study of ASG-5ME evaluated safety, pharmacokinetics, and preliminary activity of ASG-5ME in advanced pancreatic and gastric cancer patients. " 01/01/2016 - "A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers." 01/01/2016 - "Purpose ASG-5ME is an antibody-drug conjugate (ADC) targeting SLC44A4, a novel cell surface target expressed on most pancreatic and gastric cancers. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 03/10/2013 - "In addition, ASG-5ME, an antibody specific for SLC44A4 that is universally expressed in pancreatic cancer and also carries a conjugate chemotherapy particle was safe at the appropriate dosing in a phase I trial (Abstract #176). " 03/10/2013 - "Further studying of FG-3019 and ASG-5ME will show the potential activity if any of these compounds in patients with pancreatic cancer."
4.	Neoplasms (Cancer) 11/01/2016 - "Combination studies with ASG-5ME and nab-paclitaxel demonstrated combination effect in both pancreatic and prostate tumor models. " 11/01/2016 - "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer."

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	auristatin
3.	130-nm albumin-bound paclitaxel
4.	pamrevlumab
5.	monomethyl auristatin E

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Castration